• IVF Hartmann forecast full-year 2026 revenue above 2025, adjusted for volatility in the Tactical Emergency Medicine product group.
• Full-year 2026 EBIT expected to exceed 2025, despite a softer second-half growth outlook.
• Second-half growth seen slowing as temporary customer stockpiling effects fade; lower pricing from higher-cost inventories may pressure margins.
• First-half revenue rose 11.3% to CHF 85.9 million; EBIT increased to CHF 12.07 million, lifting the margin to 14% from 12.3%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IVF Hartmann Holding AG published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.